logo
Share SHARE
FONT-SIZE Plus   Neg

Rexahn Gets European Patent For Cancer Drug Archexin

Rexahn Pharmaceuticals, Inc. (RNN) said Thursday that the European Patent Office has granted the company a patent, EP 1546180, for its clinical development candidate Archexin and its use for inhibiting the activated form of Akt-1 for the treatment of cancer.

Having successfully completed a Phase IIa clinical trial of Archexin in metastatic pancreatic cancer, Rexahn has conducted an extensive scientific, clinical and business analysis of other potential indications for additional Phase IIa clinical trials with the drug.

Rexahn is now working with key clinical opinion leaders to finalize the design of a Phase IIa clinical trial in a selected tumor type and plans on updating investors on the tumor type selection and Phase IIa trial timeline in the fourth quarter of 2013.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Internet media company BuzzFeed is preparing to go public in 2018, media site Axios reported Wednesday, citing industry sources. New York-based BuzzFeed was founded in 2006 by Jonah Peretti and John Johnson III as a viral lab, focusing exclusively on tracking viral content. London Stock Exchange Group plc (LSE.L) announced the European Commission has decided to prohibit the recommended all-share merger between LSEG and Deutsche Börse (DBOEY.PK, DBOEF.PK). Despite the remedies offered by the companies, the European Commission concluded that the merger would significantly... Tinder launched a web version of its dating app, called Tinder Online, mainly focusing users in developing markets with limited storage on their mobile phones. The company also aims users in places where mobile phones are not welcome, like class rooms. Instead of swiping, they can either drag a prospective match's card to the right or left.
comments powered by Disqus
Follow RTT